A Double-Blind, Randomised, Placebo-Controlled Pharmacokinetic and Safety Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring and to Evaluate the Safety of a Matrix Vaginal Ring Containing 25 MG of Dapivirine.

Trial Profile

A Double-Blind, Randomised, Placebo-Controlled Pharmacokinetic and Safety Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring and to Evaluate the Safety of a Matrix Vaginal Ring Containing 25 MG of Dapivirine.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2011

At a glance

  • Drugs Dapivirine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors International Partnership for Microbicides
  • Most Recent Events

    • 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
    • 05 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 05 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top